港股上市公司嘉和生物-B（06998.HK）今日盘中大涨5.30%，引发市场关注。该股价上涨主要受益于公司重磅新药获批上市的利好消息。
根据公司公告，中国国家药品监督管理局（NMPA）已批准嘉和生物的来罗西利（GB491）新药上市申请。来罗西利是一种用于治疗激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性的局部晚期或转移性乳腺癌成人患者的药物。该药可与芳香化酶抑制剂联合使用作为初始内分泌治疗，或与氟维司群联合用于既往接受内分泌治疗后疾病进展的患者。
这一批准标志着嘉和生物在肿瘤治疗领域取得重大突破，有望为公司带来新的收入增长点。市场分析人士认为，随着来罗西利正式获批上市，嘉和生物在乳腺癌治疗市场的竞争力将显著提升。投资者对公司未来业绩增长的预期推动了股价的上涨。后市表现值得持续关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.